ERBB2 and gastric cancer: In this first phase 1 dose-escalation study, 22 patients with HER2-positive breast cancer, gastric cancer, or other HER2-expressing solid tumors were treated with T-DXd once every three weeks, at a dose ranging from 0.8 mg/kg to 8.0 mg/kg.